Relmada Therapeutics, Inc. (RLMD) Social Stream

Featured Post From StockTwits About RLMD

$RLMD

AXSM once thought to be a competitor in the TRD space:
Hope our Phase2/3 MONO MDD results show efficacy in December/ January and the Ketamine HAP study shows low likability in early 2022

“Back in March 2020, AXS-05 failed to show statistically significant results in a phase 3 trial investigating its efficacy against treatment-resistant depression (which is differentiated from regular depression). On top of that, this month, the company announced that the U.S. Food and Drug Administration (FDA) had revoked its breakthrough therapy designation for AXS-12, citing the approval of a competitor's cataplexy in narcolepsy treatment.”